Bayer's 2026 Forecast Dampens Investor Sentiment

Bayer secures key Roundup settlement approval but forecasts negative free cash flow and rising debt for 2026, overshadowing 2025 revenue growth.

While Bayer AG has outlined its financial performance for 2025 and achieved a critical milestone in the protracted Roundup litigation, a sobering outlook for the coming year has captured the market's attention. The company's projections for 2026 include negative free cash flow and rising debt, prompting investors to question whether legal progress can offset fundamental operational challenges.

Legal Milestones and Financial Strain

A significant development occurred on March 4th, when a Missouri court granted preliminary approval to Bayer’s proposed $7.25 billion class-action settlement related to Roundup claims. To advance the process, the company is required to deposit $500 million into a designated fund within ten days. The settlement framework now enters a crucial phase: class members have until June 4th to file objections or opt out, with a final approval hearing scheduled for July 9th.

CEO Bill Anderson has emphasized that participation must be "very close" to 100% for the settlement to hold; otherwise, Bayer reserves the right to withdraw from the agreement. Concurrently, the U.S. Supreme Court is reviewing whether federal law preempts state-level failure-to-warn claims concerning Roundup. A favorable ruling could substantially reduce the company's future liability risk.

These legal maneuvers are pivotal for Bayer's ambition to move beyond the legacy of its Monsanto acquisition. A fully successful settlement, coupled with a positive Supreme Court decision, would pave the way for the company's targeted annual margin improvement of 100 to 150 basis points through 2029.

2025 Performance: Revenue Growth Masks Underlying Pressure

For the full year 2025, Bayer reported currency-adjusted revenue of €45.6 billion, representing a slight increase. However, this top-line figure concealed notable pressures. EBITDA declined by 4.5% to €9.67 billion, heavily impacted by total legal provision charges of €7.5 billion booked throughout the year. The fourth quarter alone concluded with a net loss of €3.76 billion.

Performance across divisions was mixed. The Pharmaceuticals unit faced headwinds from patent expirations, with currency-adjusted sales of Xarelto falling 31.4% and Eylea declining 11.2%. In contrast, the Crop Science division provided a bright spot, driven by a 13.2% currency-adjusted gain in its corn seed business.

The 2026 Guidance: Rising Debt and Cash Flow Concerns

Market confidence was shaken by Bayer's forecast for the current fiscal year. The company anticipates EBITDA in a range of €9.1 billion to €9.6 billion. Notably, the upper limit of this guidance falls below the average analyst estimate of €9.67 billion. Revenue is projected to be between €44 billion and €46 billion.

The most concerning element for analysts is the expectation of a negative free cash flow, forecasted between -€1.5 billion and -€2.5 billion. This includes approximately €5 billion in anticipated litigation payments. As a direct consequence, net financial debt is expected to climb to €32-33 billion, up from roughly €29.8 billion at the end of 2025.

This cautious outlook has already been reflected in the share price, which trades near €39—approximately 20% below its 52-week high. The upcoming Annual General Meeting on April 24th, where a stable dividend of €0.11 per share is proposed, is likely to be overshadowed by the decisive legal and financial developments expected this summer.